Investors
We are backed by leading life-science investors including INKEF Capital, Novo Holdings, The Roche Venture Fund, Lundbeckfonden BioCapital and Jeito Capital.
If you would like to learn more about NMD Pharma, our latest corporate highlights and work in neuromuscular disease, please send us an email.
INKEF Capital is an innovative venture capital firm dedicated to supporting European early-stage companies in both the healthcare/life sciences and technology sectors. INKEF is distinct from other funds in that its 20-year fund life and €500 million fund size, allows it to be a long-term partner, supporting ventures through their different stages of development. With 15 investment professionals, the INKEF team has a multidisciplinary set of backgrounds in complementary technical and operational fields as well as geographies, which enables them to provide a rounded and international perspective and broad network to ensure that the portfolio companies reach their full global potential.
Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life sciences investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
The Roche Venture Fund is the corporate venture fund of Roche and invests in innovative life science companies. Over the past 20 years, the Roche Venture Fund has invested in over 60 companies globally and currently has a portfolio of around 30 companies located in 10 countries. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally and co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Lundbeckfonden BioCapital is the early stage investment unit of the Lundbeck Foundation, one of the largest industrial foundations in Denmark with a market value of around USD 10 billion. In addition to the three subsidiaries, Lundbeck, ALK-Abelló and Falck, the Foundation manages a portfolio of 25 life science investments in Europe and the US and owns a portfolio of securities of more than USD 3 billion.
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States.